TACROLIMUS — all Canadian products
29 DINs
27 marketed/approved
0 in shortage
Every Health Canada Drug Identification Number whose active ingredient is TACROLIMUS, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02456109 | ACH-TACROLIMUS | ACCORD HEALTHCARE INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 5 MG | Marketed | |
| 02454068 | ACH-TACROLIMUS | ACCORD HEALTHCARE INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 0.5 MG | Marketed | |
| 02456095 | ACH-TACROLIMUS | ACCORD HEALTHCARE INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 1 MG | Marketed | |
| 02296462 | ADVAGRAF | ASTELLAS PHARMA CANADA INC | Capsule (Extended-Release) | Oral | TACROLIMUS 0.5 MG | Marketed | |
| 02296470 | ADVAGRAF | ASTELLAS PHARMA CANADA INC | Capsule (Extended-Release) | Oral | TACROLIMUS 1 MG | Marketed | |
| 02296489 | ADVAGRAF | ASTELLAS PHARMA CANADA INC | Capsule (Extended-Release) | Oral | TACROLIMUS 5 MG | Marketed | |
| 02331667 | ADVAGRAF | ASTELLAS PHARMA CANADA INC | Capsule (Extended-Release) | Oral | TACROLIMUS 3 MG | Marketed | |
| 02459213 | APO-TACROLIMUS | APOTEX INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 0.5 MG | Approved | |
| 02474514 | APO-TACROLIMUS CAPSULES | APOTEX INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 5 MG | Approved | |
| 02474506 | APO-TACROLIMUS CAPSULES | APOTEX INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 1 MG | Approved | |
| 02485885 | ENVARSUS PA | KNIGHT THERAPEUTICS INC. | Tablet (Extended-Release) | Oral | TACROLIMUS 1 MG | Marketed | |
| 02485893 | ENVARSUS PA | KNIGHT THERAPEUTICS INC. | Tablet (Extended-Release) | Oral | TACROLIMUS 4 MG | Marketed | |
| 02485877 | ENVARSUS PA | KNIGHT THERAPEUTICS INC. | Tablet (Extended-Release) | Oral | TACROLIMUS 0.75 MG | Marketed | |
| 02569264 | JAMP TACROLIMUS OINTMENT | JAMP PHARMA CORPORATION | Ointment | Topical | TACROLIMUS 0.1 % | Approved | |
| 02531399 | LEO PHARMA - TACROLIMUS | LEO PHARMA GEN, A DIVISION OF LEO PHARMA INC. | Ointment | Topical | TACROLIMUS 0.03 % | Approved | |
| 02531380 | LEO PHARMA - TACROLIMUS | LEO PHARMA GEN, A DIVISION OF LEO PHARMA INC. | Ointment | Topical | TACROLIMUS 0.1 % | Approved | |
| 02243144 | PROGRAF | ASTELLAS PHARMA CANADA INC | Capsule | Oral | TACROLIMUS 0.5 MG | Marketed | |
| 02175983 | PROGRAF | ASTELLAS PHARMA CANADA INC | Capsule | Oral | TACROLIMUS 5 MG | Marketed | |
| 02176009 | PROGRAF | ASTELLAS PHARMA CANADA INC | Solution | Intravenous | TACROLIMUS 5 MG | Marketed | |
| 02175991 | PROGRAF | ASTELLAS PHARMA CANADA INC | Capsule | Oral | TACROLIMUS 1 MG | Marketed | |
| 02244149 | PROTOPIC | LEO PHARMA INC | Ointment | Topical | TACROLIMUS 0.03 % | Marketed | |
| 02244148 | PROTOPIC | LEO PHARMA INC | Ointment | Topical | TACROLIMUS 0.1 % | Marketed | |
| 02528592 | SANDOZ TACROLIMUS XR | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | Oral | TACROLIMUS 0.5 MG | Marketed | |
| 02528606 | SANDOZ TACROLIMUS XR | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | Oral | TACROLIMUS 1 MG | Marketed | |
| 02528614 | SANDOZ TACROLIMUS XR | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | Oral | TACROLIMUS 2 MG | Approved | |
| 02528622 | SANDOZ TACROLIMUS XR | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | Oral | TACROLIMUS 3 MG | Marketed | |
| 02528630 | SANDOZ TACROLIMUS XR | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | Oral | TACROLIMUS 5 MG | Marketed | |
| 02460238 | JAMP-TACROLIMUS | JAMP PHARMA CORPORATION | Capsule (Immediate-Release) | Oral | TACROLIMUS 0.5 MG | Cancelled Pre Market | |
| 02453428 | TARO-TACROLIMUS | SUN PHARMA CANADA INC | Capsule (Immediate-Release) | Oral | TACROLIMUS 5 MG | Cancelled Pre Market |
Browse other molecules: